Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naïve Subjects

RDEA806 is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with potent in vitro activity against wild-type and NNRTI-resistant HIV-1. A phase 2a randomized, double-blind, placebo-controlled, dose-escalating study evaluated the short-term antiviral activity, safety, and pharmacokinetics...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Moyle, Graeme, Boffito, Marta, Stoehr, Albrecht, Rieger, Armin, Shen, Zancong, Manhard, Kimberly, Sheedy, Beth, Hingorani, Vijay, Raney, Anneke, Nguyen, Mai, Nguyen, Tranh, Ong, Voon, Yeh, Li-Tain, Quart, Barry
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2010
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2916334/
https://ncbi.nlm.nih.gov/pubmed/20498326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00268-10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados